RMDN2

Across TCGA pan-cancer cohorts, RMDN2 Mutation is linked to patient survival in 6 of 34 cancer types, making it a survival-associated RMDN2 data layer compared with 24 for mass-spec protein and 6 for mass-spec protein.

The strongest signal is observed in cervical squamous cell carcinoma and endocervical adenocarcinoma (CESC), where higher RMDN2 Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated RMDN2 expression acts as an unfavorable survival marker, although some lineages such as UCEC show a favorable association.

CESC, UCEC, and LUSC are the cancer types where RMDN2 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
CESC	DFS	Median	II,III,IV	0.053	0.786	<.001	36	view →
UCEC	DFS	Median	All	0.973	0.827	.014	20	view →
LUSC	OS	Median	III,IV	0.112	0.664	.003	15	view →
LUAD	OS	Median	All	0.017	0.788	<.001	15	view →
UCS	OS	Median	All	0.185	0.686	.034	6	view →
SKCM	OS	Median	III,IV	0.179	0.721	<.001	3	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

RMDN2–CESC (DFS)

Open the CESC breakdown →